NAUT Nautilus Biotechnology: יתרת חוב לטווח ארוך של החברה

Nautilus Biotechnology (NAUT) derives its competitive advantage from patents on precision proteome mapping, which create a barrier for traditional biotech. The company aims to capture the digital DNA niche by expanding its IT solutions into research centers. The price action of the securities with the 0.02 indicator complements data on a business that integrates AI and nanotechnology to sell intellectual software without maintaining its own production.

For a portfolio analyst, identifying fundamental leaders requires evaluating long-term liabilities as a measure of financial leverage and capital structure stability. This indicator captures the volume of borrowed funds with maturities exceeding one year, which, in the context of the development of the Nautilus Biotechnology (NAUT) AI proteomics platform, reflects investments in creating a technological moat, while an analysis of the firm's long-term debt on GURU.Markets allows for an assessment of debt load risk.